Company Overview and News

41
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

2018-08-14 seekingalpha - 1
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
MBIO REDIF APOP RDHL ACER ARQL MGTX STML CLRBZ CLRBW MCUJF ABBV CLRB APOPW ALNY ABBV VNRX

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-08-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLRB

13
Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

2018-08-13 globenewswire - 1
MADISON, Wis., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of Ewing’s sarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________
CLRB

12
CLRB / Cellectar Biosciences, Inc. FORM 10-Q (Quarterly Report)

2018-08-10 sec.gov
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLRB

29
Your Daily Pharma Scoop: Theravance Positive, Denali Encouraging, Redhill Clarifies Data

2018-08-03 seekingalpha - 1
Theravance Biopharma (TBPH) reported positive data of a four-week data from a Phase 2 clinical trial of TD-9855. The candidate is an once-daily norepinephrine and serotonin reuptake inhibitor. It is indicated in patients with rare disorder called symptomatic neurogenic orthostatic hypotension (‘nOH). A person with the disorder is characterized by low pressure when she stands up.
REDIF CERC BLRX RDHL TROV CLRBZ CLRBW DNLI RXII TBPH CLRB NMRD

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-08-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________
CLRB

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-07-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLRB

12
CLRB / Cellectar Biosciences, Inc. 424B4 (Prospectus)

2018-07-27 sec.gov
Prospectus Filed pursuant to Rule 424(b)(4)
CLRB

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-07-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________
CLRB

14
Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering 

2018-07-27 globenewswire - 2
MADISON, Wis., July 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB) (“Cellectar” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of $14.4 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.
LTS-A CLRB LTS CLRBZ CLRBW

12
CLRB / Cellectar Biosciences, Inc. S-1MEF

2018-07-27 sec.gov
As filed with the Securities and Exchange Commission on July 26,
CLRB

83
Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

2018-07-20 seekingalpha - 1
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement.
MBRX ADAP ENZ AZN KPTI OVID CTIC CTI LLY CLRBZ SNY CLRBW CBIO IMMU JNJ NVS CLRB PFE ATOS

39
Your Daily Pharma Scoop: Voyager Advances, Roche Succeeds, Eisai Positive

2018-07-19 seekingalpha - 2
Voyager advancing gene therapy for Parkinson's, Phase 2 data may be sufficient for U.S. marketing application
SGEN AST RCUS ACIU BAX CLRBZ CLRBW VYGR PULM TRPX CLRB AXON

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-07-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________
CLRB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 15117F120